MediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial Report
MediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial Report
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) reported its financial results for the three months ended September 30, 2023, with a revenue of C$8.5 million. This reflects a decrease of around C$1 million sequentially but an increase of C$1.3 million over the year.
Medipharm Labs Co 多伦多证券交易所股票代码：LABS）（OTCQB: MEDIF）（FSE：MLZ）公布了截至2023年9月30日的三个月的财务业绩，其中包括 收入为850万加元。这反映出连续减少约100万加元，但同比增加了130万加元。
CEO David Pidduck emphasized the company's focus on margins, cost reductions and profitability, noting the strong balance sheet and improved profitability for strategic investments in revenue growth.
首席执行官 大卫皮德杜克 强调了公司对利润率、成本降低和盈利能力的关注，并指出收入增长方面的战略投资资产负债表强劲，盈利能力有所提高。
Q3 2023 Financial Highlights
2023 年第三季度财务亮点
- Gross profit of C$2.4M or 28%, positive for the fourth consecutive quarter and the highest since Q4 2019.
- Adjusted EBITDA improved to negative C$2.4M, a 53% improvement over the prior year and from negative C$3.2M in Q2 2023, driven by margin expansion initiatives and cost reductions.
- Successful integration of VIVO resulted in approximately C$7M in annualized savings, with an additional restructuring in Q3 contributing about C$3M in annualized savings from Q4 2023.
- A strong balance sheet with C$13M in cash and less than C$3 million in debt as of September 30, 2023, reflects a current cash position of approximately C$19M.
- 毛利 为240万加元，占28％，连续第四个季度为正数，为2019年第四季度以来的最高水平。
- 调整后 EBITDA 在利润率扩张计划和成本降低的推动下，增至负240万加元，比上年增长53％，从2023年第二季度的负320万加元。
- VIVO的成功整合带来了约700万加元的年化储蓄，第三季度的额外重组从2023年第四季度起每年可节省约300万加元。
- 一个强大的 资产负债表 截至2023年9月30日，其现金为1300万加元，债务不到300万加元，反映出目前的现金状况约为1900万加元。
Additionally, the company settled a 'long-lasting' commercial agreement dispute receiving a total of C$9M. This includes net cash of C$7.3M collected in October, C$1M in Tilray Brands, Inc. (NASDAQ:TLRY) cannabis products, and a four-year agreement where Tilray will purchase C$0.5M of MediPharm products.
此外，该公司解决了一起 “长期” 的商业协议纠纷，总金额为900万加元。这包括10月份收取的730万加元的净现金，100万加元的净现金 Tilray Brands, Inc. 纳斯达克股票代码：TLRY）的大麻产品，以及一项为期四年的协议，根据该协议，蒂尔雷将购买50万加元的MediPharm产品。
Greg Hunter, CFO of MediPharm, highlighted continued progress in Q3, emphasizing improvements in gross margins, expense reduction, and reduced cash burn toward profitability.
格雷格亨特，MediPharm首席财务官强调了第三季度的持续进展，强调了毛利率的提高、开支的减少以及盈利方面的现金消耗减少。
Price Action
价格走势
MEDIF's shares were trading 2.23% down at $0.0503 per share on Tuesday afternoon.
周二下午，MEDIF的股价下跌2.23％，至每股0.0503美元。
Related News:
相关新闻：
- New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
- MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next
- 新的CBD和THC大麻油现已从加拿大运往澳大利亚
- MediPharm Labs 打破了特许权使用费协议、这意味着什么以及下一步会发生什么
Image by PiggyBank On Unsplash
图片由 PiggyBank On Unsplash
译文内容由第三方软件翻译。